MedPath

Phase I clinical trial of a mixed 20 peptides vaccine for castration-resistant prostate cancer (CRPC)

Phase 1
Completed
Conditions
Castration-resistant prostate cancer
Registration Number
JPRN-UMIN000008209
Lead Sponsor
Research Center for Innovative Cancer Therapy, Kurume University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

The following patients must be excluded: 1) Patients who had received pre-therapies including radiotherapy, chemotherapy or immunotherapy within 28 days before the treatment. 2) Patients who had received radiotherapy to prostate within the last 1 year before the treatment. 3) Immunosuppressive treatment using a systematic steroid within the last 1 year was not permitted except for using low-dose steroid. 4)Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 5) Patients with active multiple cancers. 6) Patients with the past history of severe allergic reactions. 7)Patients who do not agree with contraception during treatment and until 70 days after treatment. 8) Patients who had enrolled in another trial within 6 months or who are treating in another trial. 9) Patients who had received any peptides consist of a mixed 20 peptides (KRM-20). 10)Patients who are difficult to participate in this trial because of psychiatric symptoms. 11)Patients who are judged inappropriate for the clinical trial by doctors.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath